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radiation therapy (SIRT)Abstract Background: Hepatocellular carcinoma (HCC) stands for the majority of primary liver
malignancy. HCC has variable grade of vascularity according to the histological tumor grade and
underlying liver damage. Yttrium-90 radioembolization is a promising catheter-based hepatic intra-
arterial therapy for HCC that necessitates proper planning. Technetium-99m macroaggregated
albumin (Tc-99m MAA), a simulation of the treatment, is used to identify the shunting of micro-
spheres to the lungs or gastrointestinal tract.
Objective: To evaluate the relationship between the percentage of lung shunting on Tc-99m MAA
scan performed in treatment planning of Yttrium-90 (Y-90) microsphere selective internal radiation
therapy (SIRT) for HCC and the grade of tumor vascularity shown on digital subtraction hepatic
angiography.
Materials and methods: This study was conducted on 19 patients diagnosed to have HCC, based on
typical computed tomography (CT) criteria and/or elevated alpha-fetoprotein (AFP) P200 ng/ml,
and planned for Y-90 therapy. They were injected by Tc-99m MAA into the hepatic arterial terri-
tory with prior digital subtraction angiography. Tc-99m MAA scan was reviewed for extrahepatic
shunting within the abdomen. Additionally, the hepatopulmonary shunt (HPS) fraction or the lung
shunting (LS) percentage was calculated and further evaluated in relation to the grade of tumor vas-
cularity shown on digital subtraction hepatic angiography.
Table 1 The adopted scale of tum
Grade of tumor vascularity
Grade 1
Grade 2
Grade 3
334 R. Refaat, M.S. HassanResults: There was no extrahepatic accumulation of Tc-99m MAA related to umbilical, gastrodu-
odenal or splenic shunting. The LS percentage assorted among patients and ranged between 0.8%
and 42.9% with a median of 5.5%. LS more than 20% occurred in only 1 patient. Subsequent ther-
apy plan was changed accordingly in 5% of patients. The more vascular the lesion was, the higher
lung shunting percentage was detected.
Conclusion: Tc-99m MAA scan is fundamental prior to Y-90 microsphere SIRT as it minimizes the
risk of post-radioembolization complications, hence, enhancing the safety of Y-90 microsphere sub-
sequent administration. Moreover, the percentage of lung shunting varies considerably among
patients with HCC relying on the grade of tumor vascularity.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Hepatocellular carcinoma (HCC) is a visceral malignancy with
the highest annual incidence worldwide (1). HCC is the cause
of 250,000 deaths worldwide each year (2) and is the second
leading cause of cancer-related death in the world. The number
of deaths per year in HCC is virtually identical to the incidence
throughout the world (3). Early HCC is typically silent clini-
cally and the disease is often well-advanced at the ﬁrst manifes-
tation. Without treatment, there is a 5-year survival rate of less
than 5% (2). On the other hand, surgical resection and trans-
plantation produce reasonable 5-year survival rates; however,
fewer than 10% of those in whom HCC is diagnosed are can-
didates for either of these procedures. Thus, there is a need for
more effective treatments of this disease in these patients (4).
HCC is inherently chemotherapy resistant tumor (5). As
well, external radiotherapy has been regarded as ineffective
for HCC because the dose of radiation that can be delivered
to the tumor is limited by the tolerance of the non-tumorous
liver (6). Alternatively, several treatment modalities have been
developed over the past 2 decades including percutaneous and
transarterial interventions (7). All catheter-based hepatic intra-
arterial therapies aim to selectively deliver anticancer treat-
ment to tumor(s) inﬂicting lethal insult to tumors, while pre-
serving normal hepatic parenchyma. This is possible because
hepatic neoplasms preferentially derive their blood supply
from an arterial source, while, the majority of non-cancerous
liver is supplied by the portal vein (8).
Another recent advance involves the administration of yt-
trium-90 (Y-90) microspheres via the hepatic artery emitting
beta radiation (9). As Y-90 microspheres become trapped with-
in the small feeding capillaries of the tumor, they deliver high
radiation doses to the tumor with minimal toxicity to normal
liver tissues (10). Y-90 is either bound to resin (SIR-Spheres)
or embedded in a glass matrix (TheraSphere) (11). A multicen-
ter analysis for survival after radioembolization using Y-90-la-
beled resin microspheres in patients with hepatocellular
carcinoma at eight European centers provided robust evidenceor vascularity with the ﬁndings o
Findings
Mild tum
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also appeof the survival achieved with radioembolization including
those with advanced disease and few treatment options (12).
Selective internal radiation therapy (SIRT) requires appro-
priate planning (13) with determination of the degree of hepa-
topulmonary shunting (9). Furthermore, hepatopulmonary
shunting as well as reﬂux toward the gastrointestinal region
can be detected at scintigraphy with the injection of techne-
tium-99m-labeled macroaggregated albumin (Tc-99m-labeled
MAA) as a microsphere surrogate into the hepatic arterial ter-
ritory (4). This is explained in view of the fact that the MAA
particles are approximately the same size as Y-90 bearing
microspheres and have a similar pattern of microspheres distri-
bution (9).
To the best of our knowledge, there are many literatures
assessing the percentage of lung shunting detected on Tc-
99m MAA scan in patients with metastatic liver tumors;
nevertheless, there are limited literatures concerned with the
percentage of lung shunting detected on Tc-99m MAA scan
in patients with hepatocellular carcinoma. Moreover,
hepatocellular carcinoma has a variable vascularity relying
on the histological tumor grade and underlying liver damage.
Accordingly, we aimed in the current study to evaluate the
relationship between the percentage of lung shunting on
Tc-99m MAA scan performed in treatment planning of
Y-90 microsphere SIRT for hepatocellular carcinoma and
the grade of tumor vascularity shown on digital subtraction
hepatic angiography.
2. Materials and methods
2.1. Patients
This prospective study was conducted from December 2012 to
August 2013 in which 19 eligible consecutive patients were en-
rolled. These patients were diagnosed to have HCC on the ba-
sis of typical computed tomography (CT) criteria and/or
elevated alpha-fetoprotein (AFP) P200 ng/ml. As we aimed
in this study to evaluate Tc-99m-MAA scan prior to Y-90n digital subtraction angiography.
on digital subtraction hepatic angiography
or staining without an increase in the number of vessels
tumor staining with increased number of vessels
mor staining with markedly increased number of vessels which
ar dilated and tortuous with or without venous pooling
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Spheres; Sirtex Medical, Sydney, Australia) for HCC, patients
were consequently selected through fulﬁlling the criteria for
Y-90 therapy. Hence, the inclusion criteria comprised unresec-
table tumor (not eligible for resection or transplantation),
tumor <70% of the total liver volume, no evidence of
signiﬁcant extrahepatic disease and with patent main portal
vein as complete portal venous thrombosis is listed as
a contraindication to the use of the resin microsphere
device.
Additional inclusion criteria were non-compromised pul-
monary functions, adequate hepatic function (total bilirubin
level 62.0 mg/dL, albumin P2.8 g/dL, alanine or aspartate
amino-transferase levels <ﬁve times the upper limit of nor-
mal), adequate renal function (creatinine level 62.0 mg/dL),
adequate hematologic ﬁndings (granulocyte count
P1.5 · 109/L, platelet countP50 · 109/L) and absence of asci-
tes. Conversely, the exclusion criteria comprised immediate
life-threatening extrahepatic disease, complete portal vein
thrombosis, inadequate hepatic and renal functions as well
as unsatisfactory hematologic ﬁndings. Our study protocol
was approved by the Committee of Ethics and patients gave
written informed consent for their treatment.
2.2. Digital subtraction angiography
The digital subtraction angiography was performed using GE
digital angiography machine (Advantx; LCV-DLX2). First, we
performed a comprehensive visceral angiography through a
right femoral approach evaluating superior mesenteric, celiac
and hepatic arterial branches using a 4 or 5 French diagnostic
catheter. A superior mesenteric artery injection, following an
abdominal aortogram, was accomplished to assess for the pres-
ence of accessory or replaced hepatic arteries arising from the
superior mesenteric artery. A venous phase was also obtained
to evaluate the status/patency of the portal vein. As well, the
celiac trunk was selectively catheterized to evaluate the hepatic
arterial supply of the tumors. Right and left hepatic angiogra-
phy was performed to identify variant mesenteric anatomy and
to perform prompt embolization of extrahepatic vessels if nec-
essary. The parent catheter was kept in the main hepatic ar-
tery, while, a microcatheter was introduced superselectively
into the feeding branch of the tumor. If a reﬂux into the gas-
troduodenal region was identiﬁed angiographically, emboliza-
tion of the right gastric artery and/or gastroduodenal artery
was performed.
Furthermore, the tumor vascularity was graded on hepatic
angiography using a scale from 1 (mildly hypervascular) to 3
(extremely hypervascular) (Table 1).Table 2 The subdivision of the included 19 patients according
to the percentage of lung shunting detected on Tc-99m MAA
scan.
Percentage of lung shunting Number of patients (%)
65 9 (47%)
5.1–10 4 (21%)
10.1–15 3 (16%)
15.1–20 2 (11%)
>20 1 (5%)2.3. Tc-99m MAA hepatic perfusion
When the percutaneous angiographic catheter was selectively
placed in the hepatic arterial territory, 5.0 mCi of Tc-99m
MAA (Amersham Pulmonate II, UK, particle size 10–60 lm,
average 35 lm) was slowly administered. This was followed
by a ﬂush with 10 ml of normal saline and the catheter was
then removed.
2.4. Tc-99m MAA planar scintigraphy
After hemostasis at the puncture site, the patient was trans-
ported to the gamma camera suite within 15 min after injection
as scintigraphy should be performed within 1 h of Tc-99m
MAA injection to prevent false positive extrahepatic activity
due to free Tc-99m. Following this injection, images were ob-
tained using GE gamma camera (SMV; DST-Xli). Planar ante-
rior and posterior views of the chest (for both lungs) and
abdomen (for the liver and gastroduodenal region) were ac-
quired with the patient in a supine position.
Post-processing of the images was performed on an ofﬂine
workstation (GE Xeleris 1.1) to calculate the percentage of
lung shunting. Regions of interest (ROIs) were carefully drawn
around the organs (lungs and liver) on the digitized image of
planar scintigrams. For each study, ROIs were drawn on the
images of the lung-ﬁelds in the anterior and posterior views
(excluding the cardiac region). Likewise, ROIs were drawn
around the liver on both anterior and posterior views. The geo-
metric mean of the net anterior and posterior count rates was
calculated for both; lungs and liver. The hepatopulmonary
shunt (HPS) fraction or the lung shunting (LS) percentage,
the percentage of activity shunted into the pulmonary circula-
tion, is the ratio of the gamma emission count in the lung to
that in the liver in ROIs on planar scintigrams. It was calcu-
lated as the ratio of lung-counts to total-counts; the ratio of
the lung counts and the summed counts in the lungs, liver
and tumor (14).
To summarize in mathematical formula, the shunt fraction
is determined as follows:
Shunt fraction ¼ GMLung
GMLung þGMLiver  100
where GMLung and GMLiver are the geometric means of the
counts from the lung and liver respectively. Geometric means
are calculated from the anterior and posterior counts
(countsant and countspost respectively) as:
GM ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃcountsant  countspost
p
Consequently, we determined the percentage of lung shunt-
ing in patients with HCC. As well, all images were assessed for
the presence of any extrahepatic MAA deposition within the
abdomen. This was done through evaluation of images for sig-
niﬁcant amount of activity in any other organs within the
abdomen such as the gastroduodenal region. Furthermore,
we evaluated the relationship between the percentage of lung
shunting and the grade of tumor vascularity shown on digital
subtraction angiography which was performed prior to Tc-
99m MAA injection using the adopted scale. Finally, we esti-
mated the frequency with which Tc-99m MAA scan affected
Y-90 therapy planning.
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IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012) was
used for data analysis. Data were expressed as mean ± stan-
dard deviation (SD) for quantitative parametric measures, in
addition to median percentiles for quantitative non-parametric
measures and both number and percentage for categorized
data. For the comparison between more than two independent
groups for non-parametric data, Kruskall–Wallis test was
used. While, Wilcoxon rank-sum test was applied to study
the comparison between two independent groups for non-
parametric data. The probability of error (p value) at 0.05
was considered signiﬁcant, while, at 0.01 and 0.001 was consid-
ered highly signiﬁcant.
3. Results
The patients enrolled in our study were 14 male patients (74%)
and 5 female patients (26%) with mean age of 53.8 ± 6.8 years
and age range of 41–63 years. Tc-99m MAA was administered
into right and left hepatic arteries in 15 (79%) and 4 (21%) pa-
tients respectively. In view of Tc-99m MAA planar scintigra-
phy, there was no extrahepatic accumulation of Tc-99m
MAA related to umbilical, gastroduodenal or splenic shunting.
In addition, we did not observe any stomach, salivary, thyroid,
kidney or bladder activity. LS percentage varied between 0.8%
and 42.9% (Table 2). Expressing the mean LS percentage as
mean ± SD, the mean LS percentage in our study was
8.8 ± 9.7. While expressing the median LS percentage as med-
ian (percentile 25–75), the median LS percentage in our study
was 5.5% (3.3–12.8).
The subdivision of the included 19 patients according to the
percentage of LS detected on Tc-99m MAA scan is shown in
Fig. 1. LS percentage of 65 was found in 9 patients (47%),
LS percentage of 5.1–10 was found in 4 patients (21%), LS
percentage of 10.1–15 was found in 3 patients (16%) and LS
percentage of 15.1–20 was found in 2 patients (11%). Addi-
tionally, LS more than 20% occurred in only 1 patient (5%)
in whom LS was 42.9%. In this patient, Tc-99mMAA infusion
was performed into the right hepatic artery. Fatefully, we were
not able to study the relation of signiﬁcant LS percentage to
the artery of injection. Consequently, the therapy plan was
changed according to the results of Tc-99m MAA scan in thisFig. 1 The subdivision of the included 19 patients according to
the percentage of lung shunting detected on Tc-99m MAA scan.patient as Y-90 therapy was canceled for fear of post-radio-
embolization pneumonitis and Sorafenib was given instead
of Y-90 therapy. Additionally, coil embolization of the right
gastric and gastroduodenal arteries was performed in 1 patient
in whom the origin of these two vessels was close to the feeding
artery of the mass (Fig. 2).
Similarly, the subdivision of the included 19 patients
according to the grade of tumor vascularity shown on digital
subtraction hepatic angiography and based upon the previ-
ously mentioned scale is listed in Table 3. The grades of tumor
vascularity were grade 1 in 11 patients (58%), grade 2 in 5 pa-
tients (26%) and grade 3 in 3 patients (16%) (Fig. 3). The rela-
tionship between the percentage of LS detected on Tc-99m
MAA scan and the grade of tumor vascularity shown on dig-
ital subtraction hepatic angiography and based upon the pre-
viously mentioned scale is illustrated in Fig. 4. The median
LS percentages were 3.5 (2.2–4.3), 11.2 (7.95–13.2) and 17.9
(15.5–42.9) in grade 1, grade 2 and grade 3 respectively. A
highly signiﬁcant statistical difference between the median
LS percentages in the concerned grades was found with
p<0.01. Moreover, there was a highly signiﬁcant statistical
difference between the median LS percentages in grades
1 and 2 with p<0.01. Likewise, there was a statistically signif-
icant difference between the median LS percentages in grades
1 and 3 and grades 2 and 3 with p<0.05. Eventually, these im-
ply that the more vascular the lesion was, the higher lung
shunting percentage was obtained as demonstrated in Figs. 4–7.4. Discussion
Yttrium-90 microsphere radioembolization provides liver-di-
rected transarterial therapy with two distinct aspects: the ﬁrst
being the injection of embolic particles (‘‘embolization’’) as
the vehicle and the second being the delivery and administration,
via this embolic vehicle, of radiation (‘‘radio’’) (15). Addition-
ally, Y-90 bearingmicrospheres, unlike external-beam radiation
sources, are point sources of radiation that preferentially local-
ize in the peritumoral and intra-tumoral arterial vasculature
(16). Therapeutic efﬁcacy and safety of radioembolization can
be best achieved by use of careful dosimetric techniques and
treatment planning (17).Ameticulouswork-up is essential to as-
sess the appropriateness of the patient for treatment. A simula-
tion of the treatment, done with Tc-99m MAA which
approximates the size of microspheres, is used to identify the
shunting of microspheres to the lungs or gastrointestinal tract,
thus, helping to determine patient selection (18). Tc-99m
MAA particles do not normally traverse the pulmonary capil-
lary bed; therefore, their systemic distribution can be used to
determine the shunt fraction (19).
In the current study, we used the standard formula (lung to
liver ratio) and not the modiﬁed formula (lung to whole body
ratio). It was validated that the use of the whole body image in
comparison to liver only image in shunting ratios did not
change the therapy dose signiﬁcantly. Nevertheless, a signiﬁ-
cant error in Y-90 microsphere treatment dose did occur if
the ROIs were not deﬁned properly in the LS calculation from
Tc-99m MAA scan (20). Furthermore, we used the geometric
mean because it is an accurate and practical method for the
in vivo quantiﬁcation of organ and regional distribution of
radionuclide (21). As through reﬂecting anterior and posterior
counts, it provides best correction for attenuation, scatter and
AC
B
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Fig. 2 (A) Digital subtraction common hepatic artery angiogram displays the standard hepatic arterial anatomy with a short common
hepatic artery (white arrow). A right gastric artery (black arrow) is seen arising from the left hepatic artery and converging to the gastric
cardia. (B) Digital subtraction angiogram of right gastric artery prior to its coiling. (C) Angiogram of gastroduodenal artery. A coil is seen
within the right gastric artery. (D) Angiogram of the coiled gastroduodenal artery shows reﬂux mainly into the left hepatic artery and to a
lesser extent into the right hepatic artery. Coil embolization of the proximal right gastric artery is also noted.
Table 3 The subdivision of the included 19 patients according
to the grade of tumor vascularity shown on digital subtraction
hepatic angiography and based upon the previously mentioned
scale.
Grade of tumor vascularity Number of patients (%)
Grade1 11 (58%)
Grade 2 5 (26%)
Grade 3 3 (16%)
Fig. 3 The subdivision of the included 19 patients according to the
grade of tumor vascularity shown on digital subtraction hepatic
angiography and based upon the previously mentioned scale.
Fig. 4 Scatter diagram plots the percentage of lung shunting
detected on Tc-99m MAA scan against the grade of tumor
vascularity shown on digital subtraction hepatic angiography and
based upon the previously mentioned scale.
Relationship between percentage of lung shunting on Tc-99m MAA and grade of HCC vascularity 337variable detector response (22). As well, all included patients in
this study were transported to the gamma camera suite after
hemostasis at the puncture site within 15 min after Tc-99m
MAA injection. In view of the fact that the time points of mea-
surement should be strictly considered for accurate evaluation
of a shunt (19).
In this study, the HPS fraction or LS percentage varied
among the 19 patients and ranged between 0.8% and 42.9%
Anterior lung counts = 28568 Posterior lung counts = 23979
A B
Anterior liver count = 1464972   Posterior liver count = 226315
DC
E                              F
Fig. 5 Tc-99m MAA planar scintigram (A–D); planar anterior and posterior views of the chest (for both lungs) (A and B) and abdomen
(for the liver and gastroduodenal region) (C and D) with lung shunting of 4.3% as calculated from the geometric means of anterior and
posterior counts. Digital subtraction angiography images (E and F) show a left lobe diffuse mass with faint blush and is considered as
grade 1; mild tumor staining without an increase in the number of vessels.
338 R. Refaat, M.S. Hassan(mean 8.8%). Alternatively, the HPS fraction or LS percentage
ranged between 6% and 26% (mean 12.3%) in a series of 20
patients (23) and between 0.4% and 32% (mean 6.2%) in an-
other series of 67 patients (24). Jiang et al. (25) characterized
the extrahepatic distribution of Tc-99mMAA in hepatic perfu-
sion imaging studies prior to Y-90 microsphere therapy. They
obtained excessive hepatopulmonary shunting with an elevated
shunting fraction more than 10% in 23 patients (13%). On the
other hand, we found an elevated shunting fraction more than
10% in 6 patients (32%). Moreover, LS more than 20% was
found in only 1 patient in the current study. Similarly, Machac
et al. (26) found that LS was more than 20% in 2 patients.
Regarding the percentage of lung shunting and the grade of
tumor vascularity, our results also demonstrated that the de-
gree of arteriovenous shunting to the lungs was affected bythe tumor vascularity. Therefore, the pattern of blood ﬂow
through the tumor is thought to be the determining factor of
pulmonary shunting. This was elucidated as the vascular
tumor had more arteriovenous shunts and hence, higher lung
shunting. The neoplastic nature of the vessels responsible for
lung shunting was afﬁrmed by Goldberg’s ﬁnding (27). They
found that the use of the vasoactive agent angiotensin II did
not signiﬁcantly increase the baseline lung shunting in patients
with liver metastases of colorectal origin. Moreover, Jiang
et al. (25) found that patients with a diagnosis of HCC showed
higher incidence of abnormal hepatopulmonary shunting
compared with other types of tumors. This is explained by
the fact that tumor-associated arteriovenous shunting is more
common in hepatocellular carcinoma than in metastatic
disease (9).
A B
C D
Anterior liver count  = 348734
Anterior lung counts = 52806 Posterior lung counts = 24024 
E F
Posterior liver count = 544281
Fig. 6 Tc-99m MAA planar scintigram (A–D); planar anterior and posterior views of the chest (for both lungs) (A and B) and abdomen
(for the liver and gastroduodenal region) (C and D) with lung shunting of 7.6% as calculated from the geometric means of anterior and
posterior counts. Digital subtraction angiography images (E and F) show a right lobe mass with a moderately intense blush and is
considered as grade 2; moderate tumor staining and increased number of vessels.
Relationship between percentage of lung shunting on Tc-99m MAA and grade of HCC vascularity 339It is entrenched that progressive pulmonary insufﬁciency, a
life-threatening complication, secondary to radiation pneumo-
nitis, can be precluded by avoiding the use of Y-90 therapy in
any patient with marked hepatopulmonary shunting (28).
Meanwhile, high LS percentage provokes reduction of the
therapy dose (10%< LS < 20%) or even cancellation of ther-
apy (LS > 20%) (29). The therapy plan in our study was chan-
ged according to the results of Tc-99m MAA scan in only 1
patient (5%) in whom LS was 42.9%. As a result, Y-90 ther-
apy for this patient was canceled for fear of post-radioemboli-
zation pneumonitis and Sorafenib was given instead. Likewise,
Liu et al. (30) excluded three patients from treatment with
TheraSphere because of signiﬁcant hepatopulmonary shunt-
ing. Recently, Gaba and Vanmiddlesworth (31) demonstrated
that chemoembolic reduction of the lung shunt fraction
before Y-90 radioembolization in patients with extensive
tumor-related hepatopulmonary shunting allowed safe Y-90radioembolization leading to excellent tumor response and
patient survival.
In our study, there was no extrahepatic accumulation of Tc-
99m MAA related to umbilical, gastroduodenal or splenic
shunting. In addition, we did not observe any stomach, sali-
vary, thyroid, kidney or bladder activity. Conversely, Jiang
et al. (25) observed an abnormal intra-abdominal visceral
deposition in the GI tract, pancreas, spleen and umbilical vein
in 19 patients (11%). Jiang et al. (25) also found that the inci-
dence of abnormal intra-abdominal visceral deposition was
higher with infusion into the left hepatic artery or proper hepa-
tic artery/common hepatic artery compared with infusion into
the right hepatic artery. Additionally, we were not able to
study the relation of signiﬁcant LS to the artery of injection
as LS of 42.9% was detected in only 1 patient with Tc-99m
MAA infusion into the right hepatic artery; nevertheless, we
believe that signiﬁcant LS has no relation to the artery of
Anterior liver count = 484125           Posterior liver count = 269418
Anterior lung counts = 352429 Posterior lung counts = 208608 
Fig. 7 Tc-99m MAA planar scintigram (A–D); planar anterior and posterior views of the chest (for both lungs) (A and B) and abdomen
(for the liver and gastroduodenal region) (C and D) with lung shunting of 42.9% as calculated from the geometric means of anterior and
posterior counts. Digital subtraction angiography images (E and F) show a diffuse right lobe mass with intense blush and is considered as
grade 3; intense tumor staining and markedly increased number of vessels which also appear dilated and tortuous without venous pooling.
340 R. Refaat, M.S. Hassaninjection. This corresponds to Machac et al. (26) who declared
that LS was not related to artery of injection and elucidated
that mild stomach, salivary, thyroid, kidney and bladder activ-
ity appeared to be non-speciﬁc due to MAA breakdown.
It is well established that microspheres may inadvertently
reﬂux during the delivery process into extrahepatic arteries
arising from the hepatic arteries and supplying the adjacent
gastrointestinal tract; typically the right gastric and gastrodu-
odenal arteries (32). This non-target embolization may lead
to catastrophic complications such as gastrointestinal ulceration
and perforation (15). It is elucidated in view of the fact that
radiation and diminished blood supply due to embolizationby the microspheres and subsequent hypoxia may result in
ulceration and even perforation of the stomach and duode-
num (33,34). Additionally, Y-90 induced ulceration of the
stomach or duodenum can be resistant to medical therapy
and surgery may be required (35). Therefore, it is strongly rec-
ommended that if a gastrointestinal shunt is suspected on the
subsequent Tc-99m MAA scan, all potential extrahepatic feed-
ers must be embolized initially (before the ﬁrst Tc-99m MAA
injection) principally the right gastric and gastroduodenal
arteries. This is to ensure that the most common sources of
extrahepatic shunts are controlled until the operator becomes
really comfortable with the procedure (15) as the risks of reﬂux
Relationship between percentage of lung shunting on Tc-99m MAA and grade of HCC vascularity 341outweigh the minimal risk of embolizing these vessels (4).
Correspondingly, we performed superselective catheterization
of the feeding branch of the tumor which was usually distal
enough to avoid reﬂux into the gastroduodenal artery. In
addition, coil embolization of the right gastric and gastroduo-
denal arteries was performed in 1 patient in whom the origin
of these two vessels was close to the feeding artery of the
mass.
To conclude, Y-90 microsphere SIRT planning for treat-
ment of hepatocellular carcinoma necessitates prior Tc-99m
MAA scan which simulates the distribution of Y-90 micro-
spheres to maximize its therapeutic response and to minimize
the risk of post-radioembolization complications. This is
accomplished through the detection of extrahepatic shunting
to the lung or gastrointestinal tract. Hence, the occurrence of
catastrophic gastrointestinal ulcer and perforation can be
avoided by embolizing the extrahepatic visceral vessels; princi-
pally the right gastric and gastroduodenal arteries if a gastro-
intestinal reﬂux is suspected on the subsequent Tc-99m MAA
scan. Likewise, pulmonary insufﬁciency secondary to radiation
pneumonitis can be avoided by procedure cancellation in those
patients with high lung shunting. Additionally, the percentage
of lung shunting varies signiﬁcantly among patients with HCC
as more vascular tumors have more arteriovenous shunts and
hence, higher lung shunting.
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